Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALT-801 in Relapsed or Refractory Multiple Myeloma
NCT01670994Phase 2Terminated
- Sponsor
- Altor BioScience Corporation
- Start
- Aug 2012
- Primary completion
- Sep 2015
- Modality
- Recombinant Proteins and Enzymes, Modified Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of pemvidutide in multiple myeloma (MM), sponsored by Altor BioScience Corporation. Started Aug 2012; status: terminated.
02
Drugs
pemvidutide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01670994.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01670994.